Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market

Enquire | Email | Print

ISBN: GBIHC152MR
Published Date: Dec, 2011
Format: PDF
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents
The leading business intelligence provider, has released its latest research “Monoclonal Antibodies Market to 2017- Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market” which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal antibodies markets in the key geographies of the US, Europe and the Rest of The World are also covered in the report. The report also includes details about monoclonal antibodies R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of therapeutic indication, which includes HER2 Breast Cancer, Bone Metastases and Bone Loss Due to Cancer Therapy, Relapsing-remitting Multiple Sclerosis (RRMS), Metastatic Non-Small Cell Lung Cancer (NSCLC) and Rheumatoid Arthritis. Furthermore, it includes market forecasts for each of the covered therapeutic indications. The report also explores the competitive landscape with a competitive analysis of the top companies in the market. GBI Research analysis estimated the global monoclonal antibodies market to be valued at $15.6 billion in 2010, with a compound annual growth rate (CAGR) of 36.7% between 2002 and 2010. The market is forecast to grow at a CAGR of 10.6% between 2010 and 2017 and to reach $31.7billion by 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in–house analysis by the GBI Research team of experts. GBI Research analysis found the R&D pipeline for the monoclonal antibodies market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that monoclonal antibodies R&D activity will remain active for at least the next four to five years.

Scope
  • Data and analysis of the monoclonal antibodies market in the leading geographies of the world: the US and Europe. The indications treated by different classes of MAbs discussed, which are covered in this report are in breast cancer, bone loss & metastasis, RRMS, NSCLC and rheumatoid arthritis.
  • Annualized market data for the monoclonal antibodies market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
  • Key drivers and restraints that have had significant impact on the market.
  • Competitive landscape of the global monoclonal antibodies market including benchmarking of the top companies. The key companies analysed in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Eli Lilly
Reasons to Buy
  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Monoclonal Antibodies Market to 2017: Executive Summary
2.1 Monoclonal Antibodies are the Largest Class of Biotherapeutic Drugs
2.2 Successful MAbs such as Rituxan, Avastin and Remicade have Received Regulatory Approvals for Multiple Indications, which Further Increased the Patient Base
2.3 Enormous Market Size for MAbs in Diseases Associated With Genetic Mutations Such As Oncology and Autoimmune Diseases
3 Monoclonal Antibodies Market to 2017: Introduction
3.1 GBI Research Report Guidance
4 Monoclonal Antibodies Market to 2017: Market Characterization
4.1 Introduction
4.1.1 Stability in the Body
4.1.2 Systemic Cancer Treatment
4.1.3 Targeted Therapy
4.2 Monoclonal Antibody Technology
4.2.1 Hybridoma Technology
4.2.2 FuCell Technology
4.3 Revenue Forecasts – Global
4.3.1 Prescription Population
4.3.2 Annual Cost of Therapy
4.3.3 Revenue
4.4 Revenue Forecasts – Countrywise
4.4.1 US
4.4.2 Europe
4.4.3 Rest of the World (ROW)
4.5 Treatment Usage Patterns
4.5.1 The US
4.5.2 Europe
4.5.3 ROW
4.6 Annual Cost of Therapy
4.6.1 The US
4.6.2 Europe
4.6.3 ROW
4.7 Global MAbs Trends
4.7.1 Market Trends
4.7.2 Technology Trends
4.8 Product Trends
4.8.1 Research and Development Focus Shifted Towards Humanized and Fully Human MAbs
4.9 Global MAbs Market Drivers
4.9.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth
4.9.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy
4.9.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs
4.9.4 Expanded Indications Opens up New Potential Patient Groups
4.9.5 Lack of Generics Augmented the Sales Growth of MAbs
4.10 Global MAbs Market Restraints
4.10.1 High Cost of MAbs Hampering the Growth of Treatment Population
4.10.2 Adverse Effects – Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy
4.10.3 Industry Challenges – Majority of MAbs Receive Approvals as Last Option Therapies
4.11 Unmet Needs
4.11.1 Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients
4.11.2 MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation
5 Monoclonal Antibodies Market to 2017: Breast Cancer (Adjuvant and Metastatic)
5.1 Overview
5.2 Introduction
5.3 Prescription Population
5.3.1 Global
5.3.2 The US
5.3.3 Europe
5.3.4 ROW
5.4 Annual Cost of Therapy
5.4.1 Global
5.4.2 The US
5.4.3 Europe
5.4.4 ROW
5.5 Market Size
5.5.1 The US
5.5.2 Europe
5.5.3 ROW
5.6 Marketed Products
5.6.1 Herceptin (trastuzumab)
5.7 Pipeline Analysis
5.7.1 Phase lll
5.7.2 Phase ll
5.7.3 Phase l
5.7.4 Preclinical/Discovery
5.8 Promising Molecules
5.8.1 Pertuzumab (2C4, trade name Omnitarg)
5.8.2 Ramucirumab (IMC-1121B)
6 MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy
6.1 Introduction
6.2 Epidemiology
6.3 Diagnosis
6.4 Treatment
6.5 Prescription Population
6.5.1 Global
6.5.2 The US
6.5.3 Europe
6.5.4 ROW
6.6 Annual Cost of Therapy
6.6.1 Global
6.6.2 The US
6.6.3 Europe
6.6.4 ROW
6.7 Market Size
6.7.1 Global
6.7.2 The US
6.7.3 Europe
6.7.4 ROW
6.8 Marketed Products
6.8.1 Xgeva (denosumab)
6.9 Pipeline Analysis
6.9.1 NDA Filed
6.9.2 Phase ll
6.9.3 Phase l
6.9.4 Preclinical/Discovery
7 MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS)
7.1 Introduction
7.2 Epidemiology
7.3 Diagnosis
7.4 Treatment
7.5 Prescription Population
7.5.1 Global
7.5.2 The US
7.5.3 Europe
7.5.4 ROW
7.6 Annual Cost of Therapy
7.6.1 Global
7.6.2 The US
7.6.3 Europe
7.6.4 ROW
7.7 Market Size
7.7.1 Global
7.7.2 The US
7.7.3 Europe
7.7.4 ROW
7.8 Marketed Products
7.8.1 Description
7.8.2 Mechanism of Action
7.8.3 Indications and Usage
7.8.4 Dosage
7.9 Pipeline Analysis
7.9.1 Phase lll
7.9.2 Phase ll
7.9.3 Phase l
7.9.4 Preclinical/Discovery
7.10 Promising Molecules
7.10.1 Campath (Alemtuzumab)
7.10.2 Ocrelizumab
8 MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC)
8.1 Introduction
8.2 Epidemiology
8.3 Diagnosis
8.4 Prescription Population
8.4.1 Global
8.4.2 The US
8.4.3 Europe
8.4.4 ROW
8.5 Annual Cost of Therapy
8.5.1 Global
8.5.2 The US
8.5.3 Europe
8.5.4 ROW
8.6 Market Size
8.6.1 Global
8.6.2 The US
8.6.3 Europe
8.6.4 ROW
8.7 Marketed Products
8.7.1 Avastin
8.8 Pipeline Analysis
8.8.1 Phase III
8.8.2 Phase II
8.8.3 Phase I
8.9 Promising Molecule
8.9.1 Necitimumab
8.9.2 Ramucirumab
9 Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis
9.1 Introduction
9.2 Epidemiology
9.3 Diagnosis
9.4 Treatment
9.5 Prescription Population
9.5.1 Global
9.5.2 The US
9.5.3 Europe
9.5.4 ROW
9.6 Annual Cost of Therapy
9.6.1 Global
9.6.2 The US
9.6.3 Europe
9.6.4 ROW
9.7 Market Size
9.7.1 Global
9.7.2 The US
9.7.3 Europe
9.7.4 ROW
9.8 Marketed Products
9.8.1 Rituxan
9.8.2 Remicade
9.8.3 Humira
9.8.4 Cimzia
9.8.5 Simponi
9.8.6 Actemra
9.9 Pipeline Analysis
9.9.1 Phase III
9.9.2 Phase II
9.9.3 Phase I
9.9.4 Preclinical/ Discovery Phase
9.10 Promising Molecule
9.10.1 Ofatumumab (Arzerra)
9.10.2 SAR153191(REGN88)
10 Monoclonal Antibodies Market to 2017: Competitive Landscape
10.1 Market Share Analysis
10.1.1 Major Companies
10.2 Amgen Inc
10.2.1 Company Profile
10.2.2 Marketed Products
10.2.3 SWOT Analysis
10.3 Abbott Laboratories
10.3.1 Company Profile
10.3.2 Marketed Products
10.3.3 SWOT Analysis
10.4 Johnson & Johnson
10.4.1 Company Profile
10.4.2 Marketed Products
10.4.3 SWOT Analysis
10.5 Novartis AG
10.5.1 Company Profile
10.5.2 Marketed Products
10.5.3 SWOT Analysis
10.6 Biogen Idec
10.6.1 Company Profile
10.6.2 Marketed Products
10.6.3 SWOT Analysis
10.7 Merck & Co Inc
10.7.1 Company Profile
10.7.2 Marketed Products
10.7.3 SWOT Analysis
10.8 Eli Lilly and Company
10.8.1 Company Profile
10.8.2 Marketed Products
10.8.3 SWOT Analysis
10.9 Roche
10.9.1 Company Profile
10.9.2 Marketed Products
10.9.3 SWOT Analysis
11 Monoclonal Antibodies Market to 2017: Strategic Consolidations
11.1 Deal Type
11.2 Mergers & Acquisitions
11.2.1 By Geography
11.2.2 M&A by Year
11.2.3 M&A by Value
11.2.4 Top M&A Deals
11.3 Licensing Agreement
11.3.1 By Geography
11.3.2 By Year
11.3.3 By Value
11.3.4 Licensing Agreement Deals by Value
11.3.5 Top Five Licensing Deals
11.4 Partnerships
11.4.1 By Geography
11.4.2 By Year
11.4.3 By Value
12 Monoclonal Antibodies Market to 2017: Appendix
12.1 Market Definitions
12.2 Abbreviations
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
12.3.4 Therapeutic Landscape
12.3.5 Geographical Landscape
12.3.6 Pipeline Analysis
12.3.7 Competitive Landscape
12.3.8 Expert Panel Validation
12.4 Contact Us
12.5 Disclaimer
12.6 Sources

List of Figures
Figure 1: Monoclonal Antibodies Market, Global, MAbs Share in Global Biologics Therapeutics Market (%), 2011
Figure 2: Monoclonal Antibodies Market, Global, Sales of MAbs Among Top 10 Biologic Therapeutic Molecules ($bn), 2010
Figure 3: Monoclonal Antibodies Market, Global, Drivers and Barriers, 2011
Figure 4: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2017
Figure 5: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 6: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 7: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2002-2017
Figure 8: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2002-2017
Figure 9: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2002-2017
Figure 10: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2017
Figure 11: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2017
Figure 12: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2017
Figure 13: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2017
Figure 14: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2017
Figure 15: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2017
Figure 16: Monoclonal Antibodies Market, Global, Revenue Distibution by Indication (%), 2011
Figure 17: Monoclonal Antibodies Market, Breast Cancer,Global, Prescription Population, 2002- 2017
Figure 18: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2017
Figure 19: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2017
Figure 20: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2017
Figure 21: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2017
Figure 22: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2017
Figure 23: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2017
Figure 24: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2017
Figure 25: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2002- 2017
Figure 26: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2002- 2017
Figure 27: Monoclonal Antibodies Market, Breast Cancer,Europe, Revenue Forecasts ($bn), 2002- 2017
Figure 28: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2002- 2017
Figure 29: Monoclonal Antibodies Market, HER2 Breast Cancer, Pipeline Analysis (%), 2011
Figure 30: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017
Figure 31: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017
Figure 32: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017
Figure 33: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017
Figure 34: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017
Figure 35: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017
Figure 36: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017
Figure 37: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017
Figure 38: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017
Figure 39: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017
Figure 40: Monoclonal Antibodies Market, Bone Metastasis,Europe, Revenue Forecasts ($m), 2011- 2017
Figure 41: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017
Figure 42: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2017
Figure 43: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2017
Figure 44: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2017
Figure 45: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2017
Figure 46: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2017
Figure 47: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2017
Figure 48: Monoclonal Antibodies Market, RRMS, Europe, Annual Cost of Therapy ($), 2006- 2017
Figure 49: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2017
Figure 50: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2006- 2017
Figure 51: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2006- 2017
Figure 52: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2006- 2017
Figure 53: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2009- 2017
Figure 54: Monoclonal Antibodies Market, RRMS, Pipeline Analysis, (%), 2011
Figure 55: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2017
Figure 56: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2017
Figure 57: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2017
Figure 58: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007 2017
Figure 59: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2017
Figure 60: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2017
Figure 61: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2017
Figure 62: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2017
Figure 63: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2007- 2017
Figure 64: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2007- 2017
Figure 65: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2008- 2017
Figure 66: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2007- 2017
Figure 67: Monoclonal Antibodies Market, NSCLC, Pipeline Analysis, (%), 2011
Figure 68: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2017
Figure 69: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2017
Figure 70: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2017
Figure 71: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2017
Figure 72: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2017
Figure 73: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2017
Figure 74: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2017
Figure 75: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2017
Figure 76: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2002- 2017
Figure 77: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2002- 2017
Figure 78: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue Forecasts ($bn), 2002- 2017
Figure 79: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2002- 2017
Figure 80: Monoclonal Antibodies Market, Rheumatoid Arthritis, Pipeline Analysis, (%), 2011
Figure 81: Monoclonal Antibodies Market to 2017, Global, Market share Analysis by Company (%), 2010
Figure 82: Monoclonal Antibodies Market to 2017, Amgen Inc SWOT Analysis, 2011
Figure 83: Monoclonal Antibodies Market to 2017, Abbott Laboratories SWOT Analysis, 2011
Figure 84: Monoclonal Antibodies Market to 2017, Johnson & Johnson SWOT Analysis, 2011
Figure 85: Monoclonal Antibodies Market to 2017, Novartis AG SWOT Analysis, 2011
Figure 86: Monoclonal Antibodies Market to 2017, Biogen Idec SWOT Analysis, 2011
Figure 87: Monoclonal Antibodies Market to 2017, Merck & Co Inc SWOT Analysis, 2011
Figure 88: Monoclonal Antibodies Market to 2017, Eli Lilly and Company SWOT Analysis, 2011
Figure 89: Monoclonal Antibodies Market to 2017, Roche SWOT Analysis, 2011
Figure 90: Monoclonal Antibodies Market, Strategic Consolidations, Analysis by Deal Type, 2010-2011
Figure 91: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Geography, 2011
Figure 92: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Year, 2011
Figure 93: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Value, 2011
Figure 94: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Geography, 2011
Figure 95: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Year, 2011
Figure 96: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Value, 2011
Figure 97: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Geography, 2011
Figure 98: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Year, 2011
Figure 99: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011
Figure 100: GBI Research Market Forecasting Model

List of Tables
Table 1: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2010
Table 2: Monoclonal Antibodies Market, Global, Prescription Population, 2010-2017
Table 3: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: Monoclonal Antibodies Market, Global, Revenue ($bn), 2002-2010
Table 6: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 7: Monoclonal Antibodies Market, Global, The US, Revenue ($bn), 2002-2010
Table 8: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2010-2017
Table 9: Monoclonal Antibodies Market, Global, Europe, Revenue ($bn), 2002-2010
Table 10: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2010-2017
Table 11: Monoclonal Antibodies Market, Global, ROW, Revenue ($bn), 2002-2010
Table 12: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2010-2017
Table 13: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2010
Table 14: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2010- 2017
Table 15: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2010
Table 16: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2010- 2017
Table 17: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2010
Table 18: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2010- 2017
Table 19: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2010
Table 20: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2010- 2017
Table 21: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2010
Table 22: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2010- 2017
Table 23: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2010
Table 24: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2010- 2017
Table 25: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2002- 2010
Table 26: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2010- 2017
Table 27: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2010
Table 28: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2010- 2017
Table 29: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2010
Table 30: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2010- 2017
Table 31: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2010
Table 32: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2010- 2017
Table 33: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2010
Table 34: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2010- 2017
Table 35: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2010
Table 36: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2010- 2017
Table 37: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2010
Table 38: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2010- 2017
Table 39: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2010
Table 40: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2010- 2017
Table 41: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue ($bn), 2002- 2010
Table 42: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2010- 2017
Table 43: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue ($bn), 2002- 2010
Table 44: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2010- 2017
Table 45: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue ($bn), 2002- 2010
Table 46: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue Forecasts ($bn), 2010- 2017
Table 47: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue ($bn), 2002- 2010
Table 48: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2010- 2017
Table 49: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase lll Molecules, 2011
Table 50: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase ll Molecules, 2011
Table 51: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase l Molecules, 2011
Table 52: Monoclonal Antibodies Market, HER2 Breast Cancer, Preclinical/Discovery Molecules, 2011
Table 53: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017
Table 54: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017
Table 55: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017
Table 56: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017
Table 57: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017
Table 58: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017
Table 59: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017
Table 60: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017
Table 61: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017
Table 62: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017
Table 63: Monoclonal Antibodies Market, Bone Metastasis, Europe, Revenue Forecasts ($m), 2011- 2017
Table 64: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017
Table 65: Monoclonal Antibodies Market, Bone Metastasis, NDA Filed Molecules , 2011
Table 66: Monoclonal Antibodies Market, Bone Metastasis, Phase ll Molecules , 2011
Table 67: Monoclonal Antibodies Market, Bone Metastasis, Phase l Molecules , 2011
Table 68: Monoclonal Antibodies Market, Bone Metastasis, Preclinical/Discovery Molecules , 2011
Table 69: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2010
Table 70: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2010- 2017
Table 71: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2010
Table 72: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2010- 2017
Table 73: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2010
Table 74: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2010- 2017
Table 75: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2010
Table 76: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2010- 2017
Table 77: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2010
Table 78: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2010- 2017
Table 79: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2010
Table 80: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2010- 2017
Table 81: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2006 2010
Table 82: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2010- 2017
Table 83: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2010
Table 84: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2010- 2017
Table 85: Monoclonal Antibodies Market, RRMS, Global, Revenue ($bn), 2006- 2010
Table 86: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2010- 2017
Table 87: Monoclonal Antibodies Market, RRMS,The US, Revenue ($m), 2006- 2010
Table 88: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2010- 2017
Table 89: Monoclonal Antibodies Market, RRMS,Europe, Revenue ($m), 2006- 2010
Table 90: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2010- 2017
Table 91: Monoclonal Antibodies Market, RRMS, ROW, Revenue ($m), 2009- 2010
Table 92: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2010- 2017
Table 93: Monoclonal Antibodies Market, RRMS, Phase lll Molecules, 2011
Table 94: Monoclonal Antibodies Market, RRMS, Phase ll Molecules, 2011
Table 95: Monoclonal Antibodies Market, RRMS, Phase l Molecules, 2011
Table 96: Monoclonal Antibodies Market, RRMS, Preclinical/Discovery Molecules, 2011
Table 97: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2010
Table 98: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2010- 2017
Table 99: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2010
Table 100: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2010- 2017
Table 101: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2010
Table 102: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2010- 2017
Table 103: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007- 2010
Table 104: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2010- 2017
Table 105: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2010
Table 106: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2010- 2017
Table 107: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2010
Table 108: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2010- 2017
Table 109: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2010
Table 110: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2010- 2017
Table 111: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2010
Table 112: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2010- 2017
Table 113: Monoclonal Antibodies Market, NSCLC, Global, Revenue ($bn), 2007- 2010
Table 114: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2010- 2017
Table 115: Monoclonal Antibodies Market, NSCLC, The US, Revenue ($bn), 2007- 2010
Table 116: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2010- 2017
Table 117: Monoclonal Antibodies Market, NSCLC, Europe, Revenue ($million), 2008- 2010
Table 118: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2010- 2017
Table 119: Monoclonal Antibodies Market, NSCLC, ROW, Revenue ($m), 2007- 2010
Table 120: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2010- 2017
Table 121: Monoclonal Antibodies Market, NSCLC, Phase lll Molecules, 2011
Table 122: Monoclonal Antibodies Market, NSCLC, Phase ll Molecules, 2011
Table 123: Monoclonal Antibodies Market, NSCLC, Phase l Molecules, 2011
Table 124: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2010
Table 125: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2010- 2017
Table 126: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2010
Table 127: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2010- 2017
Table 128: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2010
Table 129: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2010- 2017
Table 130: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2010
Table 131: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2010- 2017
Table 132: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2010
Table 133: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2010- 2017
Table 134: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2010
Table 135: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2010- 2017
Table 136: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2010
Table 137: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2010- 2017
Table 138: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2010
Table 139: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2010- 2017
Table 140: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue ($bn), 2002- 2010
Table 141: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2010- 2017
Table 142: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue ($bn), 2002- 2010
Table 143: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2010- 2017
Table 144: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010
Table 145: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010
Table 146: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue ($bn), 2002- 2010
Table 147: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2010- 2017
Table 148: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase III Molecules, 2011
Table 149: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase II Molecules, 2011
Table 150: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase I Molecules, 2011
Table 151: Monoclonal Antibodies Market, Rheumatoid Arthritis, Preclinical/ Discovery Phase Molecules, 2011
Table 152: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
Table 154: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
Table 155: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
Table 156: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
Table 157: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
Table 158: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
Table 159: Monoclonal Antibodies Market, Strategic Consolidations, Top M&A Deals, 2011
Table 153: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement Deals by Value, 2011
Table 161: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 219271, price: INR 213163, GBI Research

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online